Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Adagio Therapeutics, Inc.

Latest From Adagio Therapeutics, Inc.

Invivyd Moves On From Adintrevimab While Monitoring For New COVID-19 Variants

After changing its name from Adagio, Invivyd explained at IDWeek that its revised strategy is to monitor the virus for emerging variants and develop approaches to prevent or treat them.

Business Strategies Coronavirus COVID-19

Finance Watch: With Limited Fundraising Options, Biotechs Restructure To Extend Cash Runways

Mereo will reduce its headcount by 40% to focus on its lead programs while NeuBase revealed a 60% workforce reduction to extend its cash runway. Also, Invivyd (formerly Adagio), Greenlight and BioMarin announced job cuts, while Otonomy and others planned strategic shifts. 

Restructuring Financing

Coronavirus Update: FDA Tries To Control J&J’s Vaccine, Extended Use Of Paxlovid

The FDA has also moved to limit use of J&J’s COVID-19 vaccine amid reports of rare but dangerous blood clots, while Regeneron highlighted efforts to get approval for REGEN-COV in its Q1 earnings.

FDA Coronavirus COVID-19

Can Adagio’s Adintrevimab Hold Up Against Omicron BA.2?

The company will seek an EUA for the COVID-19 antibody after trial data indicated efficacy against Omicron, but studies have called into question its potency against the rapidly expanding subvariant.

Coronavirus COVID-19 Infectious Diseases
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies